Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
NCT ID: NCT05023928
Last Updated: 2025-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
25 participants
INTERVENTIONAL
2021-09-01
2024-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
NCT05307835
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
NCT05028231
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
NCT06675201
Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer
NCT02644863
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer
NCT03908671
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tumor antigen-sensitized DC vaccine
Tumor antigen-sensitized vaccine is administrated, 1-week interval, totally 2 times.
2-week later, Neo-antigen DC vaccine is administrated, 2-week interval, totally 5 times.
Tumor antigen-sensitized DC vaccine
subcutaneous administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tumor antigen-sensitized DC vaccine
subcutaneous administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Immunotherapy for preoperative；
* Karnofsky performance status 0-1;
* The postoperative pathological stage is (y) Pt + and / or N + M0 according to AJCC 8th
* Function of the main organs is normal;
* Edition Patient's written informed consent
Exclusion Criteria
* Abnormal coagulation function;
* Contagious diseases, such as HIV, HBV, HCV infection;
* Mental disorders;
* Concomitant tumors;
* Immunological co-morbidities
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sichuan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhen-Yu Ding
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhen-Yu Ding, Prof
Role: PRINCIPAL_INVESTIGATOR
Sichuan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHANT-211
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.